ClinicalTrials.gg
TerminatedNCT02928393Updated Jan 2, 2019

A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

A Phase 2 interventional study of Basmisanil and Placebo in Stroke, sponsored by Hoffmann-La Roche. Terminated at 13 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-01-02.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Low participant enrolment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 321 studies in Stroke with a site in Spain — 71 open to participants now, 89 under way, 6 of them phase 3. Stroke · Spain.

Enrollment
242nd of 244
5 · median 70
Started
2017
with 12 others
Phase 2
14 of 321
1 open now
Registered
113th of 321
by date

Among the 321 studies in Stroke with a site in Spain, this one is the 242nd largest by enrollment of the 244 interventional ones that give a count, is one of 13 that started in 2017, is one of 14 in phase 2, and was the 113th registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

71 of the 321 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 321 studies in Stroke with a site in Spain, or all of them as a file.
02

Study summary

This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.

03

Conditions studied

  • Stroke

Keywords

  • Stroke
  • Motor impairment
  • Stroke recovery
  • Middle cerebral artery stroke
  • Fugl Meyer
  • Fugl-Meyer Motor Scale (FMMS)
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiologic assessment confirming an acute middle cerebral artery ischemic stroke
  • Index stroke occurred within the past 3-4 days
  • Inpatient males and females
  • Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (\</=) 35
  • Sufficient speech, vision and hearing to participate in study evaluations

Exclusion criteria

Exclusion Criteria:

  • NIHSS greater than (>) 20
  • Severe aphasia that prevents a participant from following directions in rehabilitation
  • Significant deficit from prior strokes or pre-existing motor deficit
  • History of epilepsy, neurosurgery, severe head trauma or central nervous system infections that have residual symptomatology or have required treatment in the last 12 months
  • Known or suspected clinical seizure post-index stroke
  • History of pre-existing dementia or use of medications for dementia
  • History of pre-existing psychiatric conditions within 12 months prior to stroke
  • Due to undergo carotid surgery within the next 4 months
  • Enrollment/participation in any interventional study (clinical trial) involving an drug (unapproved) or non-drug treatment within the prior 3 months or 6 times the half-life (whichever is longer)
  • Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments
  • to magnetic resonance imaging (MRI) or conditions which render interpretation of MRI difficult
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Basmisanil

    Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.

    Drug: Basmisanil

  • Placebo comparator
    Placebo

    Placebo matched to basmisanil orally twice daily for 90 days.

    Drug: Placebo

Interventions

  • Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.

    Also known as: RO5186582

  • DrugPlacebo

    Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in FMMS Score at Day 90

    Time frame: Baseline (Day 1), Day 90

  2. Number of Participants with Adverse Events

    Time frame: Baseline (Day 1) up to 28 days after last dose of study drug (latest at Day 118)

  3. Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Day 30

    Time frame: Baseline (Day 1), Day 30

  4. Change From Baseline in MoCA Score at Day 90

    Time frame: Baseline (Day 1), Day 90

  5. Change From Baseline in National Institute of Health Stroke Scale (NIHSS) Score At Day 3

    Time frame: Baseline (Day 1), Day 3

  6. Change From Baseline in NIHSS Score At Day 10

    Time frame: Baseline (Day 1), Day 10

  7. Change From Baseline in NIHSS Score At Day 30

    Time frame: Baseline (Day 1), Day 30

  8. Change From Baseline in NIHSS Score At Day 90

    Time frame: Baseline (Day 1), Day 90

  9. Change From Baseline in NIHSS Score At 28 Days After Last Dose

    Time frame: Baseline (Day 1) and at 28 days after last dose of study drug (latest on Day 118)

  10. Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score At Day 3

    Time frame: Baseline (Day 1), Day 3

  11. Change From Baseline in C-SSRS Score At Day 30

    Time frame: Baseline (Day 1), Day 30

  12. Change From Baseline in C-SSRS Score At Day 60

    Time frame: Baseline (Day 1), Day 60

  13. Change From Baseline in C-SSRS Score At Day 90

    Time frame: Baseline (Day 1), Day 90

  14. Change From Baseline in C-SSRS Score At 28 Days After Last Dose

    Time frame: Baseline (Day 1), at 28 days after last dose of study drug (latest on Day 118)

Secondary outcomes

  1. Change From Baseline in Modified Rankin Scale (mRS) Score At Day 90

    Time frame: Baseline (Day 1), Day 90

  2. mRS Score At Day 90

    Time frame: Day 90

  3. Change From Baseline in Fugl-Meyer Assessment (FMA) Total Score at Day 90

    Time frame: Baseline (Day 1), Day 90

  4. Change From Baseline in FMA Subscale Score at Day 90

    Time frame: Baseline (Day 1), Day 90

  5. Apparent Oral Clearance (CL/F) of Basmisanil

    Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3

  6. Maximum Observed Plasma Concentration (Cmax) of Basmisanil

    Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3

  7. Apparent Volume of Distribution at Steady States (Vss) of Basmisanil

    Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3

  8. Area Under the Curve [AUC] of Basmisanil

    Time frame: Predose (Hour 0) (prior to morning dose) on Days 3, 10, 30, 90; 4 and 8 hours post-morning dose on Day 1; and 4 hours post-morning dose on Day 3

07

Study locations

13 sites
  • CHU de Besancon Hopital Jean Minjoz; Service de Neurologie
    Besançon, 25030, France
  • Hôpital Pellegrin Tripode - CHU de Bordeaux
    Bordeaux, 33076, France
  • Hopital la Cavale Blanche
    brest Cedex 2, 29609, France
  • Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B
    Clermont-Ferrand, 63003, France
  • Hôpital General - Service de neurologie; Service de neurologie
    Dijon Cedex, 21079, France
  • Hopital Purpan
    Toulouse Cedex 9, 31059, France
  • Hospital Universitario Puerta de Hierro
    Majadahonda, Madrid 28222, Spain
  • Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • La Paz University Hospital
    Madrid, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Clnico Universitario de Zaragoza
    Zaragoza, 50009, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Nov 2017, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2016
First posted
Oct 10, 2016
StartActual
Feb 20, 2017
Primary completionActual
Nov 3, 2017
CompletionActual
Nov 3, 2017
Last update
Jan 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02928393
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 10, 2016
Start date
Feb 20, 2017
Primary completion
Nov 3, 2017
Completion
Nov 3, 2017
Last update
Jan 2, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basmisanil

Start the discussion